Umbilical Cord Blood Collection and Processing for Cardiac Regeneration in Hypoplastic Left Heart Syndrome Patients
Status: | Recruiting |
---|---|
Conditions: | Cardiology |
Therapuetic Areas: | Cardiology / Vascular Diseases |
Healthy: | No |
Age Range: | Any |
Updated: | 8/23/2018 |
Start Date: | May 2012 |
End Date: | December 2020 |
Contact: | Kathryn E Lenn |
Email: | lenn.kathryn@mayo.edu |
Phone: | 507-266-6391 |
Cell-based cardiac regeneration has been the focus of acquired, adult heart disease for many
years. However, congenital heart disease with severe structural abnormalities may also be
reasonable targets for cell-based therapies. Interestingly, the pediatric heart is naturally
growing and may be the most amendable to regenerative strategies. Therefore, identifying
autologous cells (cells from the patient's own body) would be important to initiate these
studies.
This study aims to validate the use of umbilical cord blood as a source of autologous cells
for the purpose of cardiac repair of congenital heart disease. Cells will be isolated from
the cord blood to help us determine the feasibility of collection, processing, and storage of
these samples at the time of birth of infants with prenatal diagnosis of hypoplastic left
heart syndrome. This study may be useful for the development of pre-clinical and clinical
studies aimed at the long-term goal of repairing damaged heart muscle.
years. However, congenital heart disease with severe structural abnormalities may also be
reasonable targets for cell-based therapies. Interestingly, the pediatric heart is naturally
growing and may be the most amendable to regenerative strategies. Therefore, identifying
autologous cells (cells from the patient's own body) would be important to initiate these
studies.
This study aims to validate the use of umbilical cord blood as a source of autologous cells
for the purpose of cardiac repair of congenital heart disease. Cells will be isolated from
the cord blood to help us determine the feasibility of collection, processing, and storage of
these samples at the time of birth of infants with prenatal diagnosis of hypoplastic left
heart syndrome. This study may be useful for the development of pre-clinical and clinical
studies aimed at the long-term goal of repairing damaged heart muscle.
Inclusion Criteria:
- Any pregnant woman, regardless of age, with a prenatal diagnosis of HLHS
- One or both parents willing to consent to the storage of umbilical cord blood for the
specific purpose of regenerative research
- Mother is willing to provide a blood sample for serology testing
Exclusion Criteria:
- Individuals unwilling to participate
We found this trial at
2
sites
Rochester, Minnesota 55905
Principal Investigator: Susana Cantero Peral, MD PhD
Phone: 507-266-6391
Click here to add this to my saved trials
Philadelphia, Pennsylvania 19104
Principal Investigator: Jack Rychik, MD
Phone: 267-425-6614
Click here to add this to my saved trials